The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression
Abstract
OBJECTIVE: To evaluate effects of intravitreal ranibizumab on diabetic retinopathy (DR) severity over time in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) of ranibizumab for diabetic macular edema. METHODS: Participants with diabetic macular edema (n=759) were randomized to monthly sham, 0.3-mg ranibizumab, or 0.5-mg ranibizumab intravitreal injections. Macular laser was available per protocol-specified criteria. Fundus photographs, taken at baseline and periodically, were graded by a central reading center; clinical examinations were performed monthly. The main outcome measures of this report are secondary/exploratory analyses including a 2-step or more and 3-step or more change on the Early Treatment Diabetic Retinopathy Study severity scale in the study eye and a composite DR progression outcome including photographic changes plus clinically important events such as occurrence of vitreous hemorrhage or need for panretinal laser. RESULTS: At 2 years, the percentage of participants with DR progression (worsening by ≥ 2 or ≥ 3 steps) was significantly reduced in ranibizumab-treated eyes compared with sham-treated eyes, and DR regression (improving by ≥ 2 or ≥ 3 steps) was significantly more likely. The cumulative probability of clinical progression of DR as measured by the composite outcome at 2 years was 33.8% of sham-treated eyes compared with 11.2% to 11.5% of ranibizumab-treated eyes. CONCLUSIONS: Intravitreal ranibizumab reduced the risk of DR progression in eyes with diabetic macular edema, and many ranibizumab-treated eyes experienced improvement in DR severity. Because these results are exploratory, the use of intravitreal ranibizumab specifically to reduce DR progression or cause DR regression requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Sjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Chaturvedi, N. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61411-7 · Cited by 435
Cited by
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross, J. G., Glassman, A. R., Jampol, L. M., Inusah, S., Aiello, L. P., Antoszyk, A. N., Baker, C. W., Berger, B. B., Bressler, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.15217 · Cited by 784
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Metadata
- Authors
- Ip, M. S.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-09-01
- Volume
- 130
- Issue
- 9
- Pages
- 1145
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W1999957425
- Cited by
- 248
- References
- 2
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression. https://app.cochat.ai/papers/10.1001/archophthalmol.2012.1043
- The paper
- Ip, M. S. (2012). Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression. Archives of Ophthalmology. https://doi.org/10.1001/archophthalmol.2012.1043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.